Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorders, And Immunological Disorders)"
Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorders, And Immunological Disorders)"
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.